生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Bupivacaine has a strong affinity for SCN5A channels with an IC50 of 69.5 µM, making it valuable for chronic pain research[1].[2].[3]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02679560 | Femoral Fractures | Phase 2 | Recruiting | April 2019 | United States, California ... 展开 >> University of California Davis Med Center- Emergency Department Recruiting Sacramento, California, United States, 95817 Contact: Ian Brown, MD 916-734-1279 iebrown@ucdavis.edu 收起 << |
NCT02287623 | Acute Pain | Phase 4 | Completed | - | - |
NCT01429584 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.08mL 0.62mL 0.31mL |
15.39mL 3.08mL 1.54mL |
30.78mL 6.16mL 3.08mL |
参考文献 |
---|